Source 1primary paper2025MED
Toolkit/CXCR4-GVs
CXCR4-GVs
Also known as: CXCR4-targeted nanoscale biosynthetic gas vesicles, CXCR4-targeted nanoscale GVs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
CXCR4-GVs were constructed as targeted molecular probes, which can be proven to have good targeting properties to vulnerable atherosclerotic plaques.
Usefulness & Problems
Why this is useful
CXCR4-GVs are targeted molecular ultrasound probes built by combining nanoscale biosynthetic gas vesicles with a CXCR4-specific ligand. The abstract states they generate stronger and more durable plaque imaging signals than control GVs in rats.; ultrasound molecular imaging of vulnerable atherosclerotic plaques; targeted imaging of blood vessel walls and plaques
Source:
CXCR4-GVs are targeted molecular ultrasound probes built by combining nanoscale biosynthetic gas vesicles with a CXCR4-specific ligand. The abstract states they generate stronger and more durable plaque imaging signals than control GVs in rats.
Source:
ultrasound molecular imaging of vulnerable atherosclerotic plaques
Source:
targeted imaging of blood vessel walls and plaques
Problem solved
The probe is intended to enable early identification of vulnerable atherosclerotic plaques by targeting CXCR4-associated inflammatory lesions. It addresses the need for plaque-focused molecular ultrasound imaging rather than only generic vascular contrast.; adds CXCR4-directed targeting to nanoscale gas-vesicle ultrasound contrast agents for plaque identification
Source:
The probe is intended to enable early identification of vulnerable atherosclerotic plaques by targeting CXCR4-associated inflammatory lesions. It addresses the need for plaque-focused molecular ultrasound imaging rather than only generic vascular contrast.
Source:
adds CXCR4-directed targeting to nanoscale gas-vesicle ultrasound contrast agents for plaque identification
Problem links
adds CXCR4-directed targeting to nanoscale gas-vesicle ultrasound contrast agents for plaque identification
LiteratureThe probe is intended to enable early identification of vulnerable atherosclerotic plaques by targeting CXCR4-associated inflammatory lesions. It addresses the need for plaque-focused molecular ultrasound imaging rather than only generic vascular contrast.
Source:
The probe is intended to enable early identification of vulnerable atherosclerotic plaques by targeting CXCR4-associated inflammatory lesions. It addresses the need for plaque-focused molecular ultrasound imaging rather than only generic vascular contrast.
Published Workflows
Objective: Construct and evaluate a CXCR4-targeted nanoscale gas-vesicle ultrasound molecular probe for early identification of vulnerable atherosclerotic plaques.
Why it works: The workflow first establishes CXCR4 as a plaque-associated biomarker, then compares gas-vesicle formulations for vascular-wall imaging behavior, and finally tests whether CXCR4-targeted GVs show cell binding, in vivo plaque signal enhancement, plaque localization, and acceptable safety.
binding to CXCR4-associated plaque biologyaccess through plaque neovasculars and accumulation in vulnerable plaquescontrast-agent comparisonflow cytometryimmunofluorescencecell adhesion assayin vivo ultrasound imagingsafety testing
Stages
- 1.Baseline contrast-agent comparison in carotid artery(broad_screen)
This stage compares available contrast formulations to establish whether nanoscale GVs can image the vascular wall and whether PEG modification improves persistence.
Selection: Ability of GVs, SonoVue, and PEG-GVs to generate carotid artery wall contrast, including signal stability and duration.
- 2.Target-biomarker confirmation in plaques(functional_characterization)
This stage establishes that CXCR4 is present in plaques and low in normal vessels, supporting the rationale for a CXCR4-targeted probe.
Selection: Demonstration of CXCR4 expression in atherosclerotic plaques by flow cytometry and immunofluorescence.
- 3.Targeted binding and in vivo imaging evaluation(confirmatory_validation)
This stage tests whether adding CXCR4 targeting translates from biomarker rationale into measurable cell binding and stronger plaque imaging in animals.
Selection: Cell adhesion and in vivo ultrasound imaging evidence for targeting performance of CXCR4-GVs.
- 4.Plaque localization and safety assessment(secondary_characterization)
This stage checks whether the targeted vesicles physically localize within vulnerable plaques and whether the formulations appear safe by the reported assays.
Selection: Fluorescent plaque scanning for localization plus CCK8, H&E, and serum testing for safety.
Steps
- 1.Compare GVs, SonoVue, and PEG-GVs in carotid artery imagingcontrast agents under comparison
Establish baseline vascular-wall imaging capability and persistence differences among contrast formulations.
The study first needs to show that nanoscale GVs can image the vascular wall and whether PEG modification improves signal duration before evaluating targeted plaque imaging.
- 2.Measure CXCR4 expression in plaques by flow cytometry and immunofluorescence
Confirm that CXCR4 is enriched in atherosclerotic plaques relative to normal vessels.
Target-expression confirmation provides the biological rationale for constructing and testing a CXCR4-directed probe.
- 3.Test CXCR4-GV binding to ox-LDL-induced RAW264.7 cellstargeted probe being evaluated
Assess whether the targeted vesicles bind a plaque-relevant macrophage cell model.
A cell-based binding assay is a lower-complexity test of targeting behavior before or alongside in vivo plaque imaging.
- 4.Compare plaque imaging signal of CXCR4-GVs versus Con-GVs in animalstargeted probe being benchmarked in vivo
Determine whether CXCR4 targeting improves plaque imaging signal strength and durability in animals.
After establishing target rationale and cell binding, in vivo imaging tests whether those properties translate into improved plaque visualization.
- 5.Scan plaques after fluorescent vesicle injection to assess localization
Visualize whether vesicles pass through plaque neovasculars and accumulate in vulnerable plaques.
Localization imaging provides mechanistic support for the in vivo ultrasound signal by showing physical access and accumulation within plaques.
- 6.Assess safety with CCK8, H&E staining, and serum detectionformulations undergoing safety evaluation
Evaluate whether GVs, PEG-GVs, and CXCR4-GVs show acceptable safety in the reported assays.
Safety testing is needed after imaging-performance evaluation to determine whether the candidate probe remains suitable for further use.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
molecular targeting via cxcr4-directed bindingplaque accumulation after passage through plaque neovascularsultrasound contrast generation by gas vesiclesTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedoperating role: sensor
Use requires nanoscale biosynthetic gas vesicles, a CXCR4-targeting ligand, and ultrasound imaging. The paper also describes cell adhesion, in vivo imaging, and safety assays as part of evaluation.; requires CXCR4 ligand conjugation to nanoscale biosynthetic gas vesicles; requires ultrasound imaging workflow; targeting rationale depends on CXCR4 expression in plaques
The abstract does not show human clinical performance or establish therapeutic benefit. It also does not specify the ligand chemistry or full manufacturing details needed for broader deployment.; evidence in the abstract is limited to rat and cell-model experiments
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successMammalian Cell Lineapplication demoox-LDL-induced RAW264.7 cells
cell adhesion
Inferred from claim claim4 during normalization. CXCR4-GVs bind ox-LDL-induced RAW264.7 cells. Derived from claim claim4.
Source:
successMouseapplication demorat
in vivo ultrasound imaging
Inferred from claim claim5 during normalization. CXCR4-GVs generate stronger and more durable plaque imaging signals than Con-GVs in animal experiments. Derived from claim claim5.
Source:
Supporting Sources
Ranked Claims
CXCR4-GVs bind ox-LDL-induced RAW264.7 cells.
Nanoscale biosynthetic gas vesicles produce stable contrast signals on rat carotid artery walls.
PEG-GVs produce more lasting contrast signals on rat carotid artery walls than unmodified GVs.
CXCR4-GVs generate stronger and more durable plaque imaging signals than Con-GVs in animal experiments.
Fluorescently labeled CXCR4-GVs pass through plaque neovasculars and accumulate in vulnerable plaques in rats.
Safety of CXCR4-GVs was supported by CCK8 testing, H&E staining, and serum detection.
Approval Evidence
1 source4 linked approval claimsfirst-pass slug cxcr4-gvs
CXCR4-GVs were constructed as targeted molecular probes, which can be proven to have good targeting properties to vulnerable atherosclerotic plaques.
Source:
cell bindingsupports
CXCR4-GVs bind ox-LDL-induced RAW264.7 cells.
Source:
in vivo targeted imagingsupports
CXCR4-GVs generate stronger and more durable plaque imaging signals than Con-GVs in animal experiments.
Source:
plaque localizationsupports
Fluorescently labeled CXCR4-GVs pass through plaque neovasculars and accumulate in vulnerable plaques in rats.
Source:
safetysupports
Safety of CXCR4-GVs was supported by CCK8 testing, H&E staining, and serum detection.
Source:
Comparisons
Source-stated alternatives
The abstract explicitly compares CXCR4-GVs against Con-GVs and discusses related non-targeted GVs and PEG-GVs. SonoVue is also named as a comparator contrast agent in carotid artery imaging.
Source:
The abstract explicitly compares CXCR4-GVs against Con-GVs and discusses related non-targeted GVs and PEG-GVs. SonoVue is also named as a comparator contrast agent in carotid artery imaging.
Source-backed strengths
stronger and more durable plaque imaging signal than Con-GVs in animal experiments; binds ox-LDL-induced RAW264.7 cells; aggregates in vulnerable plaques after passing through plaque neovasculars
Source:
stronger and more durable plaque imaging signal than Con-GVs in animal experiments
Source:
binds ox-LDL-induced RAW264.7 cells
Source:
aggregates in vulnerable plaques after passing through plaque neovasculars
Compared with imaging
The abstract explicitly compares CXCR4-GVs against Con-GVs and discusses related non-targeted GVs and PEG-GVs. SonoVue is also named as a comparator contrast agent in carotid artery imaging.
Shared frame: source-stated alternative in extracted literature
Strengths here: stronger and more durable plaque imaging signal than Con-GVs in animal experiments; binds ox-LDL-induced RAW264.7 cells; aggregates in vulnerable plaques after passing through plaque neovasculars.
Relative tradeoffs: evidence in the abstract is limited to rat and cell-model experiments.
Source:
The abstract explicitly compares CXCR4-GVs against Con-GVs and discusses related non-targeted GVs and PEG-GVs. SonoVue is also named as a comparator contrast agent in carotid artery imaging.
Compared with imaging surveillance
The abstract explicitly compares CXCR4-GVs against Con-GVs and discusses related non-targeted GVs and PEG-GVs. SonoVue is also named as a comparator contrast agent in carotid artery imaging.
Shared frame: source-stated alternative in extracted literature
Strengths here: stronger and more durable plaque imaging signal than Con-GVs in animal experiments; binds ox-LDL-induced RAW264.7 cells; aggregates in vulnerable plaques after passing through plaque neovasculars.
Relative tradeoffs: evidence in the abstract is limited to rat and cell-model experiments.
Source:
The abstract explicitly compares CXCR4-GVs against Con-GVs and discusses related non-targeted GVs and PEG-GVs. SonoVue is also named as a comparator contrast agent in carotid artery imaging.
Compared with PEG-GVs
The abstract explicitly compares CXCR4-GVs against Con-GVs and discusses related non-targeted GVs and PEG-GVs. SonoVue is also named as a comparator contrast agent in carotid artery imaging.
Shared frame: source-stated alternative in extracted literature
Strengths here: stronger and more durable plaque imaging signal than Con-GVs in animal experiments; binds ox-LDL-induced RAW264.7 cells; aggregates in vulnerable plaques after passing through plaque neovasculars.
Relative tradeoffs: evidence in the abstract is limited to rat and cell-model experiments.
Source:
The abstract explicitly compares CXCR4-GVs against Con-GVs and discusses related non-targeted GVs and PEG-GVs. SonoVue is also named as a comparator contrast agent in carotid artery imaging.
Ranked Citations
- 1.